Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Listed Dossiers
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide
2. 2-(4-(3-fluorobenzyloxy)benzylamino)propionamide
3. Fbap Methanesulfonate
4. Fce 26743
5. Fce 28073
6. Fce-26743
7. Fce-28073
8. Nw-1015
9. Pnu 151774e
10. Pnu-151774e
11. Safinamide
12. Safinamide Methanesulfonate
13. Xadago
1. 202825-46-5
2. Safinamide Mesilate
3. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide Methanesulfonate
4. Pnu-151774e
5. Nw-1015
6. Safinamide (mesylate)
7. Safinamide Methanesulfonate
8. Pnu 151774e
9. Safinamide Mesylate [usan]
10. Fce-28073
11. Nw 1015
12. Safinamide Methansulfonate
13. Ys90v3dtx0
14. Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2s)-, Methanesulfonate (1:1)
15. 202825-46-5 (mesylate)
16. Safinamide Mesilate (jan)
17. Safinamide Mesylate (usan)
18. Safinamide Mesilate [jan]
19. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)-amino)propanamide Methanesulfonate
20. Chembl48582
21. (s)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide Methanesulfonate
22. Unii-ys90v3dtx0
23. Fce-28073(r-isomer)
24. Safinamidemesylate
25. Equfina (tn)
26. Xadago (tn)
27. Safinamide Mesylate Salt
28. Emd 1195686 Mesylate
29. Mls006010740
30. Schembl1665715
31. Dtxsid80942414
32. Hms3884o17
33. Safinamide Mesylate (fce28073)
34. Amy38833
35. Bcp16018
36. Ex-a2640
37. Hy-70057a
38. Mfcd15145475
39. S1472
40. Safinamide Mesilate [who-dd]
41. Akos015902297
42. Ccg-268636
43. Safinamide Methanesulfonate [mi]
44. Safinamide Mesylate [orange Book]
45. Ac-27739
46. As-75602
47. Pnu-151774e,fce28073
48. Smr004701699
49. Safinamide Mesylate Salt, >=98% (hplc)
50. Cs-0006742
51. Sw219452-1
52. D10191
53. J-013174
54. Q27294690
55. (s)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
56. (s)-(+)-2-(4-(3-fluorobenzyloxy) Benzylamino)propanamide, Methanesulfonate
57. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamidemethanesulfonate
58. (s)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
59. (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic Acid
60. Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (s)-, Monomethanesulfonate
Molecular Weight | 398.5 g/mol |
---|---|
Molecular Formula | C18H23FN2O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 398.13117117 g/mol |
Monoisotopic Mass | 398.13117117 g/mol |
Topological Polar Surface Area | 127 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 438 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Xadago is indicated for the treatment of adult patients with idiopathic Parkinsons disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
N04B
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34164
Submission : 2019-09-30
Status : Active
Type : II
Available Reg Filing : ASMF |
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-11-05
Pay. Date : 2020-09-28
DMF Number : 35201
Submission : 2020-09-28
Status : Active
Type : II
NDC Package Code : 73435-012
Start Marketing Date : 2020-12-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35719
Submission : 2021-03-31
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-08-04
Written Confirmation Number : WC-0127
Address of the Firm :
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-03-03
Registration Number : 434-52-ND
Manufacturer Name : Solara Active Pharma Sciences Limited
Manufacturer Address : A1/B, Sipcot Industrial Complex, Kudikadu Village Cuddalore-607 005, Tamil Nadu, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33725
Submission : 2019-03-29
Status : Active
Type : II
Date of Issue : 2020-10-06
Valid Till : 2022-12-03
Written Confirmation Number : WC-0457A2
Address of the Firm :
NDC Package Code : 72640-005
Start Marketing Date : 2019-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-10-15
Pay. Date : 2020-08-12
DMF Number : 34628
Submission : 2020-02-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28157
Submission : 2014-06-12
Status : Inactive
Type : II
Registration Number : 230MF10101
Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany
Initial Date of Registration : 2018-08-02
Latest Date of Registration :
Registrant Name : Korea Ezai Co., Ltd.
Registration Date : 2020-06-24
Registration Number : Su140-6-ND
Manufacturer Name : Merck KGaA
Manufacturer Address : Frankfurter Straße 250 D-64293 Darmstadt, Germany
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Emulsifying Agents
Excipient Details : HDK N20 Pharma is used as a pharmaceutical emulsifying agent in tablets, capsules, syrups, and solutions.
Dosage Form : Suspension
Grade : Oral, Topical
Application : Rheology Modifiers
Excipient Details : HPMC 60HD4000 is used as thickener and viscosity modifier in oral solid, liquid and topical dosage forms.
Dosage Form : Suspension
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : Titanium dioxide PRETIOX ...
Application : Coloring Agents
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
15
PharmaCompass offers a list of Safinamide Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Safinamide Mesylate manufacturer or Safinamide Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Safinamide Mesylate manufacturer or Safinamide Mesylate supplier.
PharmaCompass also assists you with knowing the Safinamide Mesylate API Price utilized in the formulation of products. Safinamide Mesylate API Price is not always fixed or binding as the Safinamide Mesylate Price is obtained through a variety of data sources. The Safinamide Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Safinamide Methanesulfonate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Safinamide Methanesulfonate, including repackagers and relabelers. The FDA regulates Safinamide Methanesulfonate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Safinamide Methanesulfonate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Safinamide Methanesulfonate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Safinamide Methanesulfonate supplier is an individual or a company that provides Safinamide Methanesulfonate active pharmaceutical ingredient (API) or Safinamide Methanesulfonate finished formulations upon request. The Safinamide Methanesulfonate suppliers may include Safinamide Methanesulfonate API manufacturers, exporters, distributors and traders.
click here to find a list of Safinamide Methanesulfonate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Safinamide Methanesulfonate DMF (Drug Master File) is a document detailing the whole manufacturing process of Safinamide Methanesulfonate active pharmaceutical ingredient (API) in detail. Different forms of Safinamide Methanesulfonate DMFs exist exist since differing nations have different regulations, such as Safinamide Methanesulfonate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Safinamide Methanesulfonate DMF submitted to regulatory agencies in the US is known as a USDMF. Safinamide Methanesulfonate USDMF includes data on Safinamide Methanesulfonate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Safinamide Methanesulfonate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Safinamide Methanesulfonate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Safinamide Methanesulfonate Drug Master File in Japan (Safinamide Methanesulfonate JDMF) empowers Safinamide Methanesulfonate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Safinamide Methanesulfonate JDMF during the approval evaluation for pharmaceutical products. At the time of Safinamide Methanesulfonate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Safinamide Methanesulfonate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Safinamide Methanesulfonate Drug Master File in Korea (Safinamide Methanesulfonate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Safinamide Methanesulfonate. The MFDS reviews the Safinamide Methanesulfonate KDMF as part of the drug registration process and uses the information provided in the Safinamide Methanesulfonate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Safinamide Methanesulfonate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Safinamide Methanesulfonate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Safinamide Methanesulfonate suppliers with KDMF on PharmaCompass.
A Safinamide Methanesulfonate written confirmation (Safinamide Methanesulfonate WC) is an official document issued by a regulatory agency to a Safinamide Methanesulfonate manufacturer, verifying that the manufacturing facility of a Safinamide Methanesulfonate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Safinamide Methanesulfonate APIs or Safinamide Methanesulfonate finished pharmaceutical products to another nation, regulatory agencies frequently require a Safinamide Methanesulfonate WC (written confirmation) as part of the regulatory process.
click here to find a list of Safinamide Methanesulfonate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Safinamide Methanesulfonate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Safinamide Methanesulfonate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Safinamide Methanesulfonate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Safinamide Methanesulfonate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Safinamide Methanesulfonate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Safinamide Methanesulfonate suppliers with NDC on PharmaCompass.
Safinamide Methanesulfonate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Safinamide Methanesulfonate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Safinamide Methanesulfonate GMP manufacturer or Safinamide Methanesulfonate GMP API supplier for your needs.
A Safinamide Methanesulfonate CoA (Certificate of Analysis) is a formal document that attests to Safinamide Methanesulfonate's compliance with Safinamide Methanesulfonate specifications and serves as a tool for batch-level quality control.
Safinamide Methanesulfonate CoA mostly includes findings from lab analyses of a specific batch. For each Safinamide Methanesulfonate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Safinamide Methanesulfonate may be tested according to a variety of international standards, such as European Pharmacopoeia (Safinamide Methanesulfonate EP), Safinamide Methanesulfonate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Safinamide Methanesulfonate USP).